Preclinical investigation of Mn(II)-diethylenetriaminepentaacetate (mangapentetate) as paramagnetic contrast agent for magnetic resonance tomography

V. Yu Usov, M. L. Belyanin, G. V. Karpova, O. Yu Borodin, V. D. Filimonov

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The preclinical evaluation of 0.5 M solution of a manganese(II)-DTPA complex (Mangapentetate, Pentamang) has been carried out in order to test the ability of manganese to be used as substitute for potentially toxic gadolinium in paramagnetic contrast agents in the MRI clinical routines. The toxicologic tests of the Mn(II) - DTPA were carried out in mice, rats, and rabbits. Liquid phantoms served for direct comparison of the ability of Mn(II) - DTPA to increase the intensity of T1-weighted SE-images to the contrast properties of the Gd(III) - DTPA (Magnevist). Normal healthy rabbits (n = 12) were used for quantification of the imaging ability of Mn(II) - DTPA. The value of LD50 in rabbits was above 10 ml/kg, rather close to that one of Gd(III) - DTPA. An increase in intensity of the T1-weighted images induced by addition of Mn(II) - DTPA in phantom tests did not differ significantly from the values obtained with Gadopentetate. Mn(II) - DTPA delivered prominent enhancement of normal kidneys in healthy rabbits as well as chest tumors in dogs.

Original languageEnglish
Pages (from-to)41-46
Number of pages6
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume71
Issue number4
Publication statusPublished - 22 Oct 2008

Fingerprint

Pentetic Acid
Magnetic resonance
Contrast Media
Tomography
Magnetic Resonance Spectroscopy
Gadolinium DTPA
Rabbits
Manganese
Poisons
Lethal Dose 50
Gadolinium
Thorax
Dogs
Magnetic resonance imaging
Kidney
Rats
Tumors
Imaging techniques
Neoplasms
Liquids

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{6c3e02cc0a284defb55826a92695342b,
title = "Preclinical investigation of Mn(II)-diethylenetriaminepentaacetate (mangapentetate) as paramagnetic contrast agent for magnetic resonance tomography",
abstract = "The preclinical evaluation of 0.5 M solution of a manganese(II)-DTPA complex (Mangapentetate, Pentamang) has been carried out in order to test the ability of manganese to be used as substitute for potentially toxic gadolinium in paramagnetic contrast agents in the MRI clinical routines. The toxicologic tests of the Mn(II) - DTPA were carried out in mice, rats, and rabbits. Liquid phantoms served for direct comparison of the ability of Mn(II) - DTPA to increase the intensity of T1-weighted SE-images to the contrast properties of the Gd(III) - DTPA (Magnevist). Normal healthy rabbits (n = 12) were used for quantification of the imaging ability of Mn(II) - DTPA. The value of LD50 in rabbits was above 10 ml/kg, rather close to that one of Gd(III) - DTPA. An increase in intensity of the T1-weighted images induced by addition of Mn(II) - DTPA in phantom tests did not differ significantly from the values obtained with Gadopentetate. Mn(II) - DTPA delivered prominent enhancement of normal kidneys in healthy rabbits as well as chest tumors in dogs.",
author = "Usov, {V. Yu} and Belyanin, {M. L.} and Karpova, {G. V.} and Borodin, {O. Yu} and Filimonov, {V. D.}",
year = "2008",
month = "10",
day = "22",
language = "English",
volume = "71",
pages = "41--46",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "4",

}

TY - JOUR

T1 - Preclinical investigation of Mn(II)-diethylenetriaminepentaacetate (mangapentetate) as paramagnetic contrast agent for magnetic resonance tomography

AU - Usov, V. Yu

AU - Belyanin, M. L.

AU - Karpova, G. V.

AU - Borodin, O. Yu

AU - Filimonov, V. D.

PY - 2008/10/22

Y1 - 2008/10/22

N2 - The preclinical evaluation of 0.5 M solution of a manganese(II)-DTPA complex (Mangapentetate, Pentamang) has been carried out in order to test the ability of manganese to be used as substitute for potentially toxic gadolinium in paramagnetic contrast agents in the MRI clinical routines. The toxicologic tests of the Mn(II) - DTPA were carried out in mice, rats, and rabbits. Liquid phantoms served for direct comparison of the ability of Mn(II) - DTPA to increase the intensity of T1-weighted SE-images to the contrast properties of the Gd(III) - DTPA (Magnevist). Normal healthy rabbits (n = 12) were used for quantification of the imaging ability of Mn(II) - DTPA. The value of LD50 in rabbits was above 10 ml/kg, rather close to that one of Gd(III) - DTPA. An increase in intensity of the T1-weighted images induced by addition of Mn(II) - DTPA in phantom tests did not differ significantly from the values obtained with Gadopentetate. Mn(II) - DTPA delivered prominent enhancement of normal kidneys in healthy rabbits as well as chest tumors in dogs.

AB - The preclinical evaluation of 0.5 M solution of a manganese(II)-DTPA complex (Mangapentetate, Pentamang) has been carried out in order to test the ability of manganese to be used as substitute for potentially toxic gadolinium in paramagnetic contrast agents in the MRI clinical routines. The toxicologic tests of the Mn(II) - DTPA were carried out in mice, rats, and rabbits. Liquid phantoms served for direct comparison of the ability of Mn(II) - DTPA to increase the intensity of T1-weighted SE-images to the contrast properties of the Gd(III) - DTPA (Magnevist). Normal healthy rabbits (n = 12) were used for quantification of the imaging ability of Mn(II) - DTPA. The value of LD50 in rabbits was above 10 ml/kg, rather close to that one of Gd(III) - DTPA. An increase in intensity of the T1-weighted images induced by addition of Mn(II) - DTPA in phantom tests did not differ significantly from the values obtained with Gadopentetate. Mn(II) - DTPA delivered prominent enhancement of normal kidneys in healthy rabbits as well as chest tumors in dogs.

UR - http://www.scopus.com/inward/record.url?scp=54049128166&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049128166&partnerID=8YFLogxK

M3 - Article

C2 - 18819440

AN - SCOPUS:54049128166

VL - 71

SP - 41

EP - 46

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 4

ER -